Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D

Table 1 Demographic features of study patients

	Chronic hepatitis B	Inactive HBsAg carriers	P value
No. of patients, n (%)	245 (86.6)	38 (13.4)
Sex (male/female)	166/79	11/27	0.852
BMI (mean ± SD, kg/m2)	25.9 ± 4.3	25.7 ± 3.6	0.914
Hemoglobin (mean ± SD, gr/dL)	14.9 ± 1.5	14.9 ± 1.6	0.949
White cell count (mean ± SD, /mm3)	6577 ± 1783	6615 ± 1599	0.959
Thrombocyte count (mean ± SD, 1000/mm3)	200 482 ± 57 762	219 727 ± 63 743	0.088
AST (mean ± SD, IU/L)	56.2 ± 51.3	25.2 ± 11.1	0.000
ALT (mean ± SD, IU/L)	91.6 ± 92.6	25.3 ± 13.2	0.000
HBeAg positivity, n (%)	57 (23.2)	0
HBV DNA (mean ± SD copies/mL)	4.9 × 108± 5.9 × 109	2.0 × 103± 2.6 × 103	0.000
Histopathological findings, n1:143
Total HAI score, median (range)	7 (1-18)
PN and BN, median (range)	2 (0-7)
ID and FN, median (range)	1 (0-4)
PI, median (range)	2 (0-4)
Fibrosis, median (range)	2 (0-4)

¹Number of patients who underwent liver biopsy. BMI: Body mass index; HAI: Histological activity index; PN: Piecemeal necrosis; BN: Bridging necrosis; ID: Intralobular degeneration; FN: Focal necrosis; PI: Portal inflammation; HBV: Hepatitis B virus; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.